17,261 trials
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Fragile X Syndrome
Primary: Contingency Naming Test (CNT) Performance Score — 37.05; 40.50; 66.94; 61.56 correct responses per minute
Unresectable Stage III · Stage IV Melanoma
Primary: Objective Response Rate (ORR) — 8.6; 9.0 Percentage of participants
Advanced Parkinson's Disease
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period — 7; 5; 0; 0 participants
Overweight · Obese
Primary: Serum IL-6 — 42.4; 34.3 (pg*hr)/mL
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Non-ocular Adverse Events. — 17; 12; 37; 35 participants
Lymphoma, B-Cell · Follicular Lymphoma
Primary: Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I) — 1.62 mg/m^2
Malignant Neoplasm
Primary: Cmax Following Single Dose of Drug — 3244; 5666; 3511 ng/ml — p=0.003
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Progression-free Survival — 29 months
Stomach Neoplasms · Esophageal Neoplasms
Primary: 6 Month Progression Free Survival — 79 percentage of participants
Venous Leg Ulcer · Venous Stasis Ulcers
Primary: The Average Percent (%) Change From Baseline in the Target Wound Area in Each Treatment Group Over the Twelve-week Double-blind Treatment Period. — -77.11; -70.15…
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Periodontal Health · Dental Plaque Accumulation
Primary: Gingival Health — 0.46; 0.18 units on a scale — p=0.015
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants